Soleno Therapeutics to Participate in Upcoming November Investor Conferences

Soleno Therapeutics (NASDAQ: SLNO), a clinical-stage biopharmaceutical company focused on rare disease therapeutics, has announced its participation in three major healthcare investor conferences in November 2024.

Rhea-AI Summary

Soleno Therapeutics (NASDAQ: SLNO), a clinical-stage biopharmaceutical company focused on rare disease therapeutics, has announced its participation in three major healthcare investor conferences in November 2024. The company will present at the Guggenheim Healthcare Innovation Conference (Nov 11, 10:00 AM ET), Stifel 2024 Healthcare Conference (Nov 18, 4:45 PM ET), and Jefferies London Healthcare Conference (Nov 20, 8:00 AM GT). Live audio webcasts and replays will be available for the Guggenheim and Jefferies events through the company's website.

Argus Session date unavailable

+0.71% session move Open Argus

Details

News Market Reaction – SLNO

The recorded move for SLNO in the trading session of this news was +0.71%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences:

Event: Guggenheim Healthcare Innovation Conference
Date: Monday, November 11, 2024
Time: 10:00 AM ET

Event: Stifel 2024 Healthcare Conference
Date: Monday, November 18, 2024
Time: 4:45 PM ET

Event: Jefferies London Healthcare Conference
Date: Wednesday, November 20, 2024
Time: 8:00 AM GT

A live audio webcast and replay of the Guggenheim and Jefferies events will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company recently submitted an NDA to the FDA, supported by its Phase 3 development program, for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS). For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Soleno Therapeutics (SLNO) presenting at the Guggenheim Healthcare Conference in 2024?

Soleno Therapeutics (SLNO) will present at the Guggenheim Healthcare Innovation Conference on Monday, November 11, 2024, at 10:00 AM ET.

Which investor conferences will Soleno Therapeutics (SLNO) attend in November 2024?

Soleno Therapeutics will attend three conferences: Guggenheim Healthcare Innovation Conference (Nov 11), Stifel 2024 Healthcare Conference (Nov 18), and Jefferies London Healthcare Conference (Nov 20).

How can investors access Soleno Therapeutics (SLNO) conference presentations?

Investors can access live audio webcasts and replays of the Guggenheim and Jefferies events through the Investors section of Soleno's website at www.soleno.life.